According to the issuance arrangement, a total of 7 new shares will be issued next week (March 14-march 18), including 1 on the science and innovation board, 2 on the main board of Shanghai Stock Exchange and 4 on the gem. According to the specific schedule, there are two on Monday and Thursday and one on the other three days.
The top three market values required for Dingge’s subscription are wankaixincai (RMB 205000), Xingtong shares (RMB 200000) and taienkang (RMB 150000). From the published P / E ratio of the issuance, Heshun technology applied for the purchase on Tuesday, up to 56.69 times (the industry P / E ratio is 25.2 times).
In terms of hot companies, Shenwan Hongyuan Group Co.Ltd(000166) securities, Guotai Junan Securities Co.Ltd(601211) securities and Huajin securities are covered in the new share subscription strategy. The company has been deeply engaged in the field of small molecule innovative drugs for ten years. At present, the company has six self-developed core products in the clinical stage. At the same time, the company and Zhengda Tianqing The 11 projects under research jointly developed by large pharmaceutical enterprises such as Shijiazhuang Pharmaceutical Group are in the clinical stage. Among them, sy-3505 is a domestic third-generation ALK inhibitor independently developed by the company and undergoing phase I clinical trial, sy-5007 is the first domestic self-developed selective RET inhibitor to enter clinical research, and sy-4835 is a product under research in the first echelon of the clinical progress of domestic Wee1 inhibitors. However, at present, all products of the company are in the R & D stage, have not yet carried out commercial production and sales, and the sales revenue of products has not yet been realized. The operating revenue is mainly the cooperative development revenue formed by the R & D of innovative drugs, which is still in a state of loss.
IPO schedule
new share fundamentals
first drug holding : a small molecule innovation company in clinical research stage. Currently, the R & D pipeline covers other important diseases such as non-small cell lung cancer, lymphoma, hepatocellular carcinoma, pancreatic cancer, thyroid cancer, ovarian cancer, leukemia and other important diseases. At present, the company has 159 authorized invention patents worldwide, and there are 22 research projects in the R & D pipeline, all of which are class 1 new drugs, of which 6 of the 11 completely self-developed projects are in the clinical stage (1 has entered the clinical stage, has entered the phase II / III clinical trial, and 1 has entered the phase II clinical trial); The 11 cooperative R & D projects are in the clinical stage (one has entered the clinical stage and has entered the phase II / III clinical trial, and two have entered the phase II clinical trial). The company Pharmablock Sciences (Nanjing) Inc(300725) carried out in-depth strategic cooperation on the development and production of API and registration and application of NDA (new drug application) of the second generation ALK inhibitor sy-707 project.
Heshun technology : China’s leading non-ferrous polyester film enterprise. The company began its own production of polyester film in 2010. From 2010 to 2020, the company developed from one production line with a production capacity of 3000 tons to five production lines with a production capacity of 42000 tons. The company has obtained a wide range of customers and has established and maintained stable cooperative relations with a number of high-quality customers, including well-known enterprises at home and abroad such as Suzhou Shihua New Material Technology Co.Ltd(688093) , Jiangsu Sidike New Materials Science & Technology Co.Ltd(300806) , Kairen precision and DYT. The products of the company’s main customers have been widely used in well-known manufacturers at home and abroad, such as apple, Samsung, Huawei, Panasonic, ZTE, oppo, LG and Dell.
Xingtong Co., Ltd. : a leading enterprise in China’s coastal bulk liquid chemical shipping industry. As of June 30, 2021, the transportation capacity of bulk liquid chemicals of the company accounted for 10.19% of the total transportation capacity of China’s coastal chemical ship market, accounting for the main share. Since the Ministry of transport adopted the macro-control policy of transport capacity in 2012, the company has accumulated 95500 DWT of new transport capacity of chemical ships, accounting for 22.32% of the new transport capacity in the market in the same period, ranking the first in the industry, and ranking the first in the four new transport capacity Reviews since 2019. The company has established long-term and stable strategic cooperative relations with Fujian United Petrochemical, Zhejiang Petrochemical, CNOOC, CNOOC shell, Hengli Petrochemical Co.Ltd(600346) , China Aviation Oil and other large petrochemical enterprises. The compound annual growth rate of the company’s three-year operating revenue was 28.2%, and the compound annual growth rate of the three-year net profit attributable to the parent company was 63.5%.
Lushan new material : the company is one of the major manufacturers of hot-melt bonding materials in China. Its products are widely used in composite building materials, energy pipelines, high barrier packaging, photovoltaic new energy, flat panel display and other fields. Among them, a variety of Functional Polyolefin hot melt rubber particles of the company have gradually realized import substitution; Hot melt adhesive film products have the comprehensive strength of products competing with leading brands, and have been fully recognized by well-known customers such as Panasonic, Jingke energy, Byd Company Limited(002594) and so on; Oil and gas pipeline anti-corrosion hot melt adhesive products occupy a competitive advantage and compete directly with foreign well-known manufacturers in the international market.
fujilai : the company is one of the enterprises with the largest production scale and the most complete product varieties of lipoic acid series products in the world. In 2020, the export volume of lipoic acid series products accounted for 37.61%, ranking second in the industry; The export volume of phosphatidylcholine series and carnosine series products ranks first in the industry. The company has established perfect marketing channels, has enjoyed a certain popularity and reputation in Europe, the United States, Japan, India, South Korea and other markets, and has accumulated a stable customer base. The company’s main well-known customers include daewoong and olons P. A., DKSH and Tokuyama are well-known enterprises in the industry.
wankaixincai : the company has a bottle grade PET production capacity of 1.8 million tons / year, and the production capacity ranks among the top in the world. In 2018, 2019 and 2020, the domestic market share of bottle grade PET of the company was 7.10%, 6.94% and 9.81% respectively; The global market share is 4.15%, 3.97% and 4.25% respectively. The company’s main customers include nongnongshan spring, Coca Cola, Yibao, Wahaha and other well-known enterprises at home and abroad. The strict access system of major brands around the world has contributed to the “moat” of the company’s business. One belt, one road, Russia, Egypt, Nigeria and other countries are sold to hundreds of countries and regions.
tynkon : the company’s main business is agent operation, R & D, production and sales of pharmaceutical products, medical devices and sanitary materials, and provision of pharmaceutical technology services and technology transfer. Since 1999, the company has been acting for the operation of Hewei Zhengchang pill and voritin. Through the successful operation of the above products, the company has set up operation outlets in the whole country. The company is focusing on accelerating the transformation and building a self-developed pipeline. At present, the company has 16 independent R & D projects, of which 4 have submitted drug registration approval applications and 1 cooperative R & D project. Among them, pramipexole hydrochloride sustained-release tablets, tadalafil tablets, ornidazole injection and argatroban injection developed by the wholly-owned subsidiary Shandong huaplatinum Kaisheng have submitted the application for drug registration approval; In addition, the company has also arranged key new drug projects such as cisplatin polymer micelles and leizumab injection.
